
Neogen Corporation NEOG
$ 9.42
-6.13%
Quarterly report 2026-Q1
added 04-09-2026
Neogen Corporation Cost of Revenue 2011-2026 | NEOG
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Neogen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 473 M | 460 M | 416 M | 284 M | 253 M | 222 M | 222 M | 212 M | 190 M | 168 M | 143 M | 125 M | 98 M | 91.6 M | 84.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 473 M | 84.9 M | 230 M |
Quarterly Cost of Revenue Neogen Corporation
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112 M | 118 M | 114 M | - | 111 M | 118 M | 112 M | - | 112 M | 113 M | 112 M | - | 110 M | 117 M | 70.1 M | 188 M | 70.8 M | 69.9 M | 68.3 M | 138 M | 62.9 M | 61.8 M | 59 M | 61.8 M | 54.5 M | 56.8 M | 53.2 M | 56.8 M | 53.2 M | 57.1 M | 52.9 M | 57.1 M | 50.4 M | 52.5 M | 49.4 M | 102 M | 47.5 M | 47.1 M | 43.2 M | 47.1 M | 43.2 M | 41.4 M | 37.1 M | 41.4 M | 34.7 M | 34.2 M | 33.5 M | 34.2 M | 33.5 M | 30.1 M | 28.2 M | 30.1 M | 28.2 M | 23.4 M | 23.2 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 188 M | 23.2 M | 66.9 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
144 M | $ 15.85 | -2.49 % | $ 171 M | ||
|
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | ||
|
Agilent Technologies
A
|
2.91 B | $ 115.06 | -0.29 % | $ 35 B | ||
|
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
15.3 M | $ 1.13 | -2.59 % | $ 6.15 M | ||
|
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | ||
|
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
45.5 M | $ 16.05 | -3.83 % | $ 855 M | ||
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | ||
|
Interpace Biosciences
IDXG
|
14.6 M | $ 2.3 | - | $ 10.2 M | ||
|
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | ||
|
Co-Diagnostics
CODX
|
222 K | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | ||
|
Castle Biosciences
CSTL
|
60.2 M | $ 23.13 | -1.28 % | $ 642 M | ||
|
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | ||
|
Danaher Corporation
DHR
|
10 B | $ 189.61 | -1.7 % | $ 135 B | ||
|
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
1.51 B | $ 120.93 | -2.22 % | $ 19.2 B | ||
|
Myriad Genetics
MYGN
|
248 M | $ 4.35 | -2.03 % | $ 403 M | ||
|
Fulgent Genetics
FLGT
|
176 M | $ 14.43 | -3.93 % | $ 436 M | ||
|
NeoGenomics
NEO
|
413 M | $ 7.69 | -3.17 % | $ 985 M | ||
|
Guardant Health
GH
|
349 M | $ 78.6 | -9.83 % | $ 9.85 B | ||
|
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
4.81 M | $ 2.13 | -0.9 % | $ 4.89 M | ||
|
Koninklijke Philips N.V.
PHG
|
9.99 B | $ 28.31 | 0.62 % | $ 20 B | ||
|
ICON Public Limited Company
ICLR
|
3.97 B | $ 106.81 | 0.1 % | $ 8.81 B | ||
|
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 260.93 | -4.51 % | $ 21.7 B | ||
|
Natera
NTRA
|
158 M | $ 193.03 | -4.91 % | $ 19 B | ||
|
Lantheus Holdings
LNTH
|
600 M | $ 80.59 | -1.03 % | $ 5.44 B | ||
|
Senseonics Holdings
SENS
|
19.5 M | $ 6.68 | 0.15 % | $ 279 M | ||
|
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K | ||
|
Soleno Therapeutics
SLNO
|
2.7 M | $ 52.63 | 0.23 % | $ 2.67 B | ||
|
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 191.51 | -3.19 % | $ 21.3 B | ||
|
ENDRA Life Sciences
NDRA
|
173 K | $ 4.94 | -6.97 % | $ 3.89 M | ||
|
Neuronetics
STIM
|
76.8 M | $ 1.35 | -2.17 % | $ 89 M |